Cargando…
Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
The incidence of serum sickness following treatment of CLL with obinutuzumab has not been fully characterized, but is likely rare. Consideration should be given to this diagnosis in appropriate circumstances so that effective corticosteroid therapy can be initiated to alleviate inflammatory symptoms...
Autores principales: | Saba, Julie, Logan, Aaron C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457998/ https://www.ncbi.nlm.nih.gov/pubmed/28588833 http://dx.doi.org/10.1002/ccr3.969 |
Ejemplares similares
-
Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
por: Khurana, Sharad, et al.
Publicado: (2019) -
Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017) -
Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus
por: Freund, Johanna, et al.
Publicado: (2022) -
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
por: Seiter, Karen, et al.
Publicado: (2015) -
Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
por: Luan, Chunyan, et al.
Publicado: (2019)